5AM Ventures

We are proud to announce the upcoming launch of TMRW Vault, our latest offering in frozen specimen storage and management. For the first time, you get the power of TMRW technology – accurate identification and tracking, advanced monitoring, EMR integration, and reduced risk of human error – all with a manual, liquid storage solution. "What truly sets TMRW apart is their dedication to adapting and enhancing their solutions to meet the unique needs of each lab and clinic," said Rebecca Holmes, PhD, HCLD, Senior Vice President, Lab Operations at CCRM Fertility. "Their deep understanding of IVF labs and ability to innovate has resulted in a solution that blends technology with the practical demands of everyday operations." 🔗 READ THE FULL RELEASE HERE: https://lnkd.in/ebSj_V7w KEY VAULT BENEFITS:  ✓ Digital Specimen Management ✓ Manual Access  ✓ Provides the specimen storage capacity of 10 traditional dewars in one-third of the footprint ✓ Advanced Monitoring with TMRW Overwatch® ✓ One day Easy Installation  ✓ EMR Integration ✓ Autofill Liquid Nitrogen

Are you interested in building and investing in the next generation of innovative life science companies? We will be hosting a virtual info session to discuss 5AM, 4:59, and our upcoming July-December 2025 Fellowship program in Boston. To learn more about 5AM and the Fellowship, please register for our virtual info session held on Monday, April 7th, 2025 from 4-5pm ET.   Founded in 2002, 5AM Ventures is an early-stage venture firm leveraging both venture creation and venture capital to bring new medicines to patients. 5AM’s fellowship program provides participants with hands-on experience and integrates fellows with active deal teams across therapeutic areas and modalities. We are seeking Fellows with strong scientific and/or medical background e.g., PhD or MD students, MBA students with relevant experience, postdocs, and clinical fellows. Info session registration: https://lnkd.in/eANkYfiZ

We are thrilled to announce that Latigo Biotherapeutics has secured $150 million in Series B funding to advance our mission of developing non-opioid pain therapeutics. This financing, led by funds managed by Blue Owl Capital, will accelerate the clinical development of our Nav1.8 inhibitors and expand our pipeline of innovative treatments. We welcome Senior Managing Director Kevin Raidy from Blue Owl Capital to our board of directors. Thank you to our new investors Deep Track Capital, Access Biotechnology, Qatar Investment Authority, Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, UPMC Enterprises, and Kern Capital as well as the further commitment of existing investors Westlake BioPartners®, Foresite Capital, 5AM Ventures, and Alexandria Venture Investments. Together, we are poised to address the urgent need for non-opioid pain solutions and improve the lives of those affected by pain. Read the full press release: https://lnkd.in/gHJFupPx #Biopharma #Biotech #Biotechnology #PharmaNews

We are incredibly grateful to our sponsor Silicon Valley Bank for their generous support and partnership of Science2Startup. SVB provides commercial and private banking to individuals and companies in the technology, life science and healthcare, private equity, venture capital and premium wine industries. Their sponsorship has been vital in making S2S a success over the years. A big thank you to Adam Tweedy and team for their time and dedication to the symposium.

Mark your calendars! Science2Startup 2025 is on May 14th at the Ragon Institute of Mass General Brigham, MIT, and Harvard in Cambridge, MA. We are thrilled to be working with Atlas Venture, F-Prime, Osage University Partners (OUP), and RA Capital Management. Thank you to the sponsors Colliers, Deloitte, Goodwin, HDMZ, and Silicon Valley Bank for bringing entrepreneurs and researchers together with top #biotech and #pharma execs, VCs, and scientists. Cambridge is a uniquely rich area for #lifescience, and we are excited to work to continue the tradition of excellence. Read the announcement below!

We are pleased to announce that we received FDA approval to expand our drug’s indication to include the treatment of edema in patients with Chronic Kidney Disease. This milestone provides a new treatment option for healthcare professionals treating edema due to CKD. We remain committed to advancing cardiorenal care and addressing unmet needs. For more details, please visit: https://lnkd.in/gUuJmBqZ #ChronicKidneyDisease #CKD #edema

We’re very pleased to share some news: The FDA has granted us Fast Track designation (FTD) for our investigational non-opioid treatment for acute pain. LTG-001 is a selective Nav1.8 inhibitor that works by blocking peripheral sensory neurons responsible for pain signals. This prevents the transmission of these pain signals to the central nervous system, thereby reducing pain. The FDA's Fast Track designation signifies that LTG-001 has the potential to address an unmet medical need in treating this serious condition. It also allows for more frequent interactions with the FDA and potentially an expedited review process. Commenting on the news, our CEO Nima Farzan, said it marks another important milestone for Latigo and that we look forward to working closely with the FDA to accelerate development. To read our full press release, click here: https://lnkd.in/gHJFupPx #BioPharma #Biotechnology #Bio #PharmaNews

#Science2Startup is taking place this May hosted by 5AM Ventures, F-Prime, Atlas Venture, Osage University Partners (OUP), and RA Capital Management. The symposium is a unique opportunity for researchers to present their #startup ideas to leading #biotech and #pharma execs, VCs, and entrepreneurs in the Boston/Cambridge area. To learn more about the event or to get involved, please email us at info@science2startup.com, visit www.science2startup.com or follow us on LinkedIn Science2Startup

We are pleased to share that the U.S. FDA has removed the clinical hold on ENTR-601-44 and authorized the initiation of ELEVATE-44-102 -- a Phase 1b multiple ascending dose clinical study in non-ambulatory and ambulatory adults living with Duchenne muscular dystrophy who are amenable to exon 44 skipping.    “Given the strength of our safety and target engagement data from our Phase 1 clinical study and the profound unmet need in adults living with Duchenne, we are pleased to have obtained FDA clearance for the ELEVATE-44-102 study,” said Dipal Doshi, CEO of Entrada Therapeutics. “The study will help assess the potential of ENTR-601-44 in both non-ambulatory and ambulatory adult patients who are unfortunately often left out of clinical studies due to the advanced stage of their disease. Nearly half of those living with Duchenne who are amenable to exon 44 skipping are adults. ELEVATE-44-102 will provide clinical experience from this important population for our growing data package in support of what we believe will be a best-in-class therapy.”   Read the full release: https://lnkd.in/eEx84qiU   You can also check out our website for recent updates to our Corporate Presentation: https://lnkd.in/e4eBUv5i   #EntradaHere #Biotech #DMD #Duchenne

We are pleased to announce that the FDA has granted both rare pediatric disease and #orphandrug designations to our lead program, EN-374, for the treatment of X-linked chronic granulomatous disease (#XCGD). CGD is a rare, severe genetic disorder that significantly impairs the immune system, leaving patients vulnerable to recurring, severe bacterial and fungal infections. This often leads to dysregulated inflammation and serious complications. We plan to submit an IND for EN-374 in the first half of this year. VP of Clinical Development Andrew Dietz, MD, MSCR shares insight below into what this exciting milestone means for Ensoma. Read more here. https://lnkd.in/eFCTp94x